CN103599125B - Radioprotective and assistant anti-tumor drug and application - Google Patents
Radioprotective and assistant anti-tumor drug and application Download PDFInfo
- Publication number
- CN103599125B CN103599125B CN201310600627.6A CN201310600627A CN103599125B CN 103599125 B CN103599125 B CN 103599125B CN 201310600627 A CN201310600627 A CN 201310600627A CN 103599125 B CN103599125 B CN 103599125B
- Authority
- CN
- China
- Prior art keywords
- group
- tumor
- radioprotective
- compared
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of radioprotective and assistant anti-tumor drug and application, is mix obtained by extracting by decoction and alcohol sedimentation technique the ginseng polysaccharide, lentinan and the blazei polysaccharide that obtain from natural plants Radix Ginseng, Lentinus Edodes and Tricholoma matsutake (lto et lmai) Singer with 1:1:1 mass ratio as active component.The peroral dosage form that any one routine made by any pharmaceutically acceptable carrier or adjuvant is aided with, as tablet, oral liquid, capsule etc. with this active component.Medicine of the present invention has raising body's immunity, adjunct antineoplastic and radiation resistance; the antitumor curative effect applied with chemotherapy drugs in combination is obviously better than being used alone chemotherapeutics; and the body injury caused can be treated by therapeutical chemistry; interior free yl can be removed; hemopoietic function protecting, is applicable to the radiation-induced body injury of prevention and therapy.
Description
Technical field
The present invention relates to a kind of by natural plant extracts as the radioprotective of active component and assistant anti-tumor drug, particularly a kind of can adjunct antineoplastic, conditioner body immunity function, radiation hazradial bundle is had to the polysaccharide mixture of defencive function.
Background technology:
Malignant tumor is one of major disease of serious threat human health, and in China, over nearly 20 years, tumor mortality rate rises nearly 3 one-tenth, has become the highest disease of mortality rate.Estimate according to World Health Organization (WHO), along with world population aging increasingly, estimate that whole world number of cancer deaths is by continuations rising, may by more than 1,310 ten thousand to the year two thousand thirty.Because Incidence is agnogenio, there is no effective prevention method at present, in addition ecological deterioration, crowd's life, the sickness rate of malignant tumor remains high.The treatment of malignant tumor at present still with operative treatment, radiotherapy, chemotherapy for main method.But radiotherapy and chemotherapy to there is specificity poor, and the drawback of damage can be caused to body's immunity.Therefore develop low, the eutherapeutic anticancer active constituent of toxicity and tumor patient immunologic function can be improved, especially the cellular immune function of patient is improved, and then alleviate the preparation of toxic and side effects of Radiotherapy chemotherapy, for the generation of prophylaxis of tumours, the therapeutic effect improving tumor is significant.
Polysaccharide is extensively present in the cell wall of animal, plant and microorganism, and being the natural macromolecular material linked together by glycosidic bond by aldose or ketose, is the important composition composition of all Living organisms, and relevant with the necessary several functions that sustains life.Large quantifier elimination shows, vegetable polysaccharides has antitumor action, and these polysaccharide, while performance antitumor action, almost do not have lethal effect to normal zooblast.Therefore polysaccharide has become one of Main way of current anti-cancer agent development.Lentinan is the agent of typical T lymphocyte activator, inside and outside all can strengthen the delayed hypersensitivity of normal or immunologic hypofunction mice, the generation of promotion cytotoxic T cell, raising CTL kill and wound vigor.Meanwhile, lentinan can also induce generation one to have immunocompetent cytokine, activating complement system, and enhancing antibody generates, and macrophage lysosomal enzyme and IL-1 secretory volume are increased, thus the defence played tumor cell and lethal effect.Ginseng polysaccharide can induce autochthonous tumor necrosin, strengthens the activity of NK cell and CTL cell, has enhancing and activation, the side effect that ameliorate tumor chemicotherapy causes to normal mouse and tumor-bearing mice body's immunity.Though blazei polysaccharide biological activity has report both at home and abroad, all do not carry out the analysis and research of system.Results of Animal display in the early stage blazei polysaccharide of this seminar has significant protective effect to radiogenic immune function of mice damage.Because different polysaccharide is by the antitumor action of different mechanism raising body, we propose such hypothesis for this reason, different polysaccharide is mixed with mixture according to a certain percentage, after entering body, antitumor and the radiation resistance of body will be improved by different approach.
Summary of the invention
The object of the present invention is to provide a kind of energy adjunct antineoplastic, radioprotective and conditioner body immunity function and the radioprotective had no side effect and assistant anti-tumor drug.
Radix Ginseng (Panaxginseng) is Araliaceae perennial root herbaceous plant, has anti-inflammatory, anti-stress, radiation protection, resisting fatigue, immunomodulating and the anti-ageing effect of waiting for a long time.Lentinus Edodes (lentinusedodes), also known as Lentinus Edodes, Flammulina velutipes, Lentinus Edodes etc., belongs to Basidiomycetes Agaricaceae, is that edible fungi is held concurrently one of medicinal fungus, has high protein, low fat, polysaccharide, several amino acids and multivitamin characteristic.Tricholoma matsutake (lto et lmai) Singer (Tricholomamatsutake) is under the jurisdiction of Basidiomycota in classification of fungi system, Tricholoma, belong to medicine food dual purpose plant, delicious flavour is unique, be rich in several amino acids, vitamin, trace element and polysaccharide, rich in nutritive value, there are some researches show that Tricholoma matsutake (lto et lmai) Singer has immune-enhancing activity and stronger radioprotective is active.
The present inventor is found by lot of experiments, ginseng polysaccharide in Radix Ginseng can induce autochthonous tumor necrosin (TNF), tumor cell is killed and wounded and inhibitory action, enhancing and activation is had, the side effect that ameliorate tumor chemicotherapy causes to normal mouse and tumor-bearing mice body's immunity.After lentinan in Lentinus Edodes enters body, induction generation one has immunocompetent cytokine, and under the comprehensive function of these cytokines, body immune system function strengthens, and can play defence and lethal effect to tumor cell.Blazei polysaccharide in Tricholoma matsutake (lto et lmai) Singer has significant protective effect to radiogenic immune function of mice damage.Accordingly, radioprotective of the present invention and assistant anti-tumor drug are proposed.
Radioprotective of the present invention and assistant anti-tumor drug, mix obtained by extracting by decoction and alcohol sedimentation technique the ginseng polysaccharide, lentinan and the blazei polysaccharide that obtain from natural plants Radix Ginseng, Lentinus Edodes and Tricholoma matsutake (lto et lmai) Singer as active component with 1:1:1 mass ratio.
The peroral dosage form that any one routine made by any pharmaceutically acceptable carrier or adjuvant is aided with, as tablet, oral liquid, capsule etc. with this active component.
Medicine of the present invention has raising body's immunity, adjunct antineoplastic and radiation resistance; the antitumor curative effect applied with chemotherapy drugs in combination is obviously better than being used alone chemotherapeutics; and the body injury caused can be treated by therapeutical chemistry; interior free yl can be removed; hemopoietic function protecting, is applicable to the radiation-induced body injury of prevention and therapy.
The pharmacodynamics test of medicine of the present invention is as follows:
One, extracorporeal anti-tumor function pharmacodynamic experiment
(1) test medicine is on the impact of CTL killing activity
1. experiment material
RPMI-1640 culture fluid, calf serum, trypsin, LDH test kit, P815 cell etc.
2. experimental procedure
Aseptic taking-up mouse spleen, is ground, and crosses 200 order cells sieves, after adding ammonia chloride splitting erythrocyte, adds PBS and wash three times, centrifugally abandon supernatant.Add the RPMI-1640 medium preparing splenocyte suspension containing 10%FBS, respectively by low (Lowdose, 300 μ g/ml), in (Mediumdose, 600 μ g/ml), high (Highdose, 1200 μ g/ml) medicine of three dosage and lymphocyte hatch 24h jointly, and set up blank group (Control), with culture fluid adjustment cell concentration 1 × 10
7cells/ml, adds in 96 orifice plates by splenocyte suspension, 100 μ l/ holes.Using mouse hypertrophy cell oncocyte (P815) as the target cell detecting T cell cytotoxic activity, 96 orifice plates are added than 20:1 according to effect target, establish target cell Spontaneous release hole and maximum release aperture simultaneously, in CO2 incubator after Dual culture 24h, collecting cell supernatant, add LDH reagent, after question response is complete, detect the absorbance value at 490nm place.SPSS statistical software is used to carry out statistical disposition.
Cytotoxic activity (%)=[(the spontaneous release aperture of experiment release Kong –)/(the spontaneous release aperture of maximum release Kong –)] × 100
3. experimental result
The affect experimental result of tested material on CTL killing activity refers to Fig. 1.Shown in figure, * represents that, compared with Control group, P<0.05, has significant difference; # represents that, compared with Mediumdose group, P<0.05, has significant difference.Compared with Control group, low dosage, middle dosage and high dose medicament all can the killing activities (P<0.05) of remarkable enhanced CT L, the killing activity of the CTL of middle dose drug group is significantly higher than low dosage and high dose group (P<0.05), therefore the most obvious with the effect of middle dose drug group.
(2) test medicine is on the impact of NK killing activity
1. experiment material
RPMI-1640 culture fluid, calf serum, trypsin, LDH test kit, YAC-1 cell etc.
2. experimental procedure
Target cell is mouse lymphoma cell strain (YAC-1), and all the other steps are with (one).
3. experimental result
Tested material refers to Fig. 2 on the experimental result that affects of NK killing activity.Shown in figure, * represents that, compared with Control group, P<0.05, has significant difference; # represents that, compared with Mediumdose group, P<0.05, has significant difference.Compared with Control group, low dosage, middle dosage and high dose medicament all significantly can strengthen the killing activity (P<0.05) of NK cell, the killing activity of the NK cell of middle dose drug group is significantly higher than low dosage and high dose group (P<0.05), therefore the most obvious with the effect of middle dose drug group.
Two, Anticancer effect in vivo pharmacodynamic experiment
(1) tested material is to the tumor-inhibiting action of tumor-bearing mice
1. experiment material
ICR mice, H22 cell, RPMI-1640 culture fluid, calf serum, trypsin etc.
2. experimental procedure
Cleaning grade ICR mice, male and female half and half, are purchased from Jilin University's preclinical medicine portion animal center, 20 ± 2g, 40, H22 tumor cell suspension are inoculated in mouse back subcutaneous, 1.5 × 10
5mice only, is divided into 4 groups by H22cells/ at random, often organizes 10, i.e. tumor model matched group (model), chemotherapeutic group (FU), medicine group (PM), medicine+chemotherapeutic group (PM+FU); 24h after tumor cell transplantation, gives different process factors respectively, and chemotherapeutic is by intraperitoneal injection (30mg/kg), and medicine is by the mode administration of gavage.After 20 days, eyeball gets blood, and mice is put to death in dislocation, takes out tumor, weighs and measure its volume, getting the test experience of spleen tissue for follow-up immunization function.SPSS statistical software is used to carry out statistical disposition.
3. experimental result
The tumor-inhibiting action experimental result of tested material to tumor-bearing mice refers to Fig. 3.Shown in figure, * represents that, compared with model group, P<0.05, has significant difference; # represents that, compared with PM group, P<0.05, has significant difference; + represent that, compared with FU group, P<0.05, has significant difference.Compared with model group, PM group, FU group and FU+PM group tumor weight and volume significantly reduce (P<0.05), and the tumor killing effect of FU+PM group is obviously better than PM group and FU group (P<0.05).
(2) tested material is on the impact of the immunologic function of tumor-bearing mice
1. experiment material
RPMI-1640 culture fluid, calf serum, trypsin, LDH test kit, P815 cell, YAC-1 cell etc.
2. experimental procedure
(1) test medicine is on the impact of CTL killing activity: experimental procedure is with " one, (one) ".
(2) test medicine is on the impact of NK killing activity: experimental procedure is with " one, (one) ".
3. experimental result
(1) the affect experimental result of test medicine on CTL killing activity is shown in Fig. 4.Shown in figure, * represents that, compared with model group, P<0.05, has significant difference; # represents that, compared with PM group, P<0.05, has significant difference; + represent that, compared with FU group, P<0.05, has significant difference.Compared with model group, the CTL killing activity of PM group and FU+PM group significantly raises (P<0.05), and FU group CTL killing activity significantly reduces (P<0.05).PM can remarkable enhanced CT L killing activity.
(2) the affect experimental result of test medicine on NK killing activity is shown in Fig. 5.Shown in figure, * represents that, compared with model group, P<0.05, has significant difference; # represents that, compared with PM group, P<0.05, has significant difference; + represent that, compared with FU group, P<0.05, has significant difference.Compared with model group, the NK cell killing activity of PM group and FU+PM group significantly raises (P<0.05), and FU group NK cell killing activity significantly reduces (P<0.05).PM can significantly strengthen NK cell killing activity.
(3) tested material is on the impact of the immunologic function relevant cell factor activity of tumor-bearing mice
1. experiment material
TNF-α ELISA kit, IL-2ELISA test kit, IL-4ELISA test kit and IFN-γ ELISA kit etc.
2. experimental procedure
Eyeball of mouse is got blood, centrifugal, obtain serum.Measure the TNF-α in serum, IL-2, IL-4 and IFN-γ level.SPSS statistical software is used to carry out statistical disposition.
3. experimental result
(1) tested material is shown in Fig. 6 to the experimental result that affects of TNF-alpha levels in tumor-bearing mice serum.Shown in figure, * represents that, compared with model group, P<0.05, has significant difference; # represents that, compared with PM group, P<0.05, has significant difference; + represent that, compared with FU group, P<0.05, has significant difference.Compared with model group, in PM group and FU+PM group serum, TNF-alpha levels significantly raises (P<0.05), and FU group TNF-alpha levels significantly reduces (P<0.05).PM can significantly improve the TNF-alpha levels in tumor-bearing mice body.
(2) tested material is tested the impact of IL-2 level in tumor-bearing mice serum and be the results are shown in Figure 7.Shown in figure, * represents that, compared with model group, P<0.05, has significant difference; # represents that, compared with PM group, P<0.05, has significant difference; + represent that, compared with FU group, P<0.05, has significant difference.Compared with model group, in PM group and FU+PM group serum, IL-2 level significantly raises (P<0.05), and FU group IL-2 level significantly reduces (P<0.05).PM can significantly improve the IL-2 level in tumor-bearing mice body.
(3) tested material is tested the impact of IL-4 level in tumor-bearing mice serum and be the results are shown in Figure 8.Shown in figure, * represents that, compared with model group, P<0.05, has significant difference; # represents that, compared with PM group, P<0.05, has significant difference; + represent that, compared with FU group, P<0.05, has significant difference.Compared with model group, in PM group and FU+PM group serum, IL-4 level significantly reduces (P<0.05), and FU group IL-4 level significantly raises (P<0.05).PM significantly can reduce the IL-4 level in tumor-bearing mice body.
(4) tested material is tested the impact of IFN-γ level in tumor-bearing mice serum and be the results are shown in Figure 9.Shown in figure, * represents that, compared with model group, P<0.05, has significant difference; # represents that, compared with PM group, P<0.05, has significant difference; + represent that, compared with FU group, P<0.05, has significant difference.Compared with model group, in PM group and FU+PM group serum, IFN-γ level significantly raises (P<0.05), and FU group IFN-γ level significantly reduces (P<0.05).PM can significantly improve the IFN-γ level in tumor-bearing mice body.
Three, radiation resistance pharmacodynamic experiment in body
(1) test medicine irradiates the protective effect of mice oxidative function to gamma-rays
1. experiment material
MDA, SOD and CAT test kit, ICR mice.
2. experimental procedure
Cleaning grade ICR mice, male and female half and half, be purchased from Jilin University's preclinical medicine portion animal center, 20 ± 2g, 150, be divided into Normal group (NC), radiation matched group (IC) and medicine low dose group (600mg/kg), middle dosage group (1200mg/kg), high dose group (2400mg/kg) three test medicine groups at random, every day gastric infusion; Normal group and radiation matched group give the normal saline of equivalent, successive administration 14 days, and the gamma-rays all accepting 4Gy dosage on the 15th day except Normal group irradiates, within 1st, 3,7 day, often organize after irradiation and get 10, totally 50, eyeball gets blood, centrifugal, obtain serum.Measure MDA, SOD and CAT level in serum.SPSS statistical software is used to carry out statistical disposition.
3. experimental result
Tested material refers to table 1 to table 3 to the protective effect experimental result that gamma-rays irradiates mice oxidative function.
Shown in table 1-3, * represents compared with Normal group, and P<0.05 has significant difference; # represents that, compared with radiation matched group, P<0.05, has significant difference.
Table 1 illustrates, accept gamma-rays and irradiate latter 1st, 3 day, compared with Normal group, the MDA level of radiation matched group and three dose medication regimen groups all significantly raises (P<0.05), and the MDA level of irradiation control group is significantly higher than the medication therapy groups (P<0.05) of each dosage.Accept gamma-rays and irradiate latter 7th day, compared with Normal group, the MDA level of radiation matched group and low-dose drugs treatment group all significantly raises (P<0.05), middle dosage and high dose medicament treatment group there was no significant difference (P>0.05).
Table 2 illustrates, accept gamma-rays and irradiate latter 1st, 3,7 day, compared with Normal group, the SOD level of radiation matched group and three dose medication regimen groups all significantly reduces (P<0.05), and the SOD level of irradiation control group is significantly lower than the medication therapy groups (P<0.05) of each dosage.
Table 3 illustrates, accept gamma-rays and irradiate latter 1st, 3 day, compared with Normal group, the CAT level of radiation matched group and three dose medication regimen groups all significantly reduces (P<0.05), and the CAT level of irradiation control group is significantly lower than the medication therapy groups (P<0.05) of each dosage.Accept gamma-rays and irradiate latter 7th day, compared with Normal group, the CAT level of radiation matched group and low-dose drugs treatment group all significantly reduces (P<0.05), middle dosage and high dose medicament treatment group there was no significant difference (P>0.05).
Table 1. test medicine on gamma-rays irradiate MDA level in mice serum impact (
± s, nmol/mL)
Note: * p<0.05 compares with Normal group, and #p<0.05 compares with radiation matched group
Table 2. test medicine on gamma-rays irradiate SOD activity in mice serum impact (
± s, U/mL)
Note: * p<0.05 compares with Normal group, and #p<0.05 compares with radiation matched group
Table 3. test medicine on gamma-rays irradiate CAT activity in mice serum impact (
± s, U/mL)
Note: * p<0.05 compares with Normal group, and #p<0.05 compares with radiation matched group
(2) test medicine irradiates the protective effect of mouse immune system to gamma-rays
1. experiment material
RPMI-1640, hyclone.
2. experimental procedure
(1) modelling is with (one)
(2) splenocyte is to canavaline A(ConA) reactive mensuration:
Adopt tetramethyl azo azoles salt (MTT) method.Adjustment mouse boosting cell concentration to 1 × 10
7individual/ml, ConA concentration is 10 μ g/ml, and on 96 well culture plates, every hole adds the splenocyte of 100 μ l, and three wells established by each sample, stimulate hole to have no time and add 100 μ lConA, the every hole of cell control well adds 100 μ l culture fluid, in incubator, cultivate 48h, stops cultivating adding 20 μ lMTT(5mg/ml in first 4 hours), after cultivation terminates, sucking-off supernatant, every hole adds 150 μ lDMSO, and application microplate reader measures absorbance at 490nm place.
3. experimental result
Test medicine irradiates the protective effect experimental result of mouse immune system in table 4 to gamma-rays.Shown in table, * represents compared with Normal group, and P<0.05 has significant difference; # represents that, compared with radiation matched group, P<0.05, has significant difference.Accept gamma-rays and irradiate latter 1st, 3,7 day, compared with Normal group, radiation matched group and three dose medication regimen group mouse boosting cell ConA proliferative induction reactions significantly reduce (P<0.05), and the reaction of the ConA proliferative induction of irradiation control group is significantly lower than the medication therapy groups (P<0.05) of each dosage.
Table 4. test medicine on gamma-rays irradiate the reaction of mouse boosting cell ConA proliferative induction impact (
± s)
Note: * p<0.05 compares with Normal group, and #p<0.05 compares with radiation matched group
(3) test medicine irradiates the protective effect of mouse hemopoietic system to gamma-rays
1. experiment material
Hydrochloric acid, calcium chloride, perchloric acid.
2. experimental procedure
(1) modelling is with (one)
(2) mensuration of number of white blood cells (WBC) in peripheral blood:
Respectively at pre-irradiation, irradiate the rear 3rd and 7 days collection peripheral blood 20 μ l, add in 0.38ml1% hydrochloric acid, after mixing, add in blood counting chamber.
Leukocyte count (10
9/ L)=tetra-generous grid nucleated cell sum/4 × 10
7× extension rate
(3) mensuration of bone marrow DNA content:
Take out femur, draw the CaCl of 10ml5mmol/L
2solution, pours in centrifuge tube by whole bone marrow, under 4 DEG C of conditions, place 30min, and the centrifugal 15min of 2500r/min, discards supernatant, adds the HClO of 0.2mol/L in precipitate
4solution 5ml, fully mixes, 90 DEG C of water-bath 15min, and after being cooled to room temperature, the centrifugal 15min of 3500r/min, gets supernatant, measures absorbance A 260 be worth with ultraviolet spectrophotometer at 260nm place.
DNA(μg)=40×50×A（260nm）。
3. experimental result
(1) test medicine irradiates the impact of mouse peripheral blood leukocyte count in table 5 to gamma-rays.Shown in table, * represents compared with Normal group, and P<0.05 has significant difference; # represents that, compared with radiation matched group, P<0.05, has significant difference.Accept gamma-rays pre-irradiation, compared with Normal group, radiation matched group and three dose medication regimen group mouse peripheral bloods leukocyte count there was no significant difference (P>0.05), accept gamma-rays and irradiate latter 3rd, 7 day, compared with Normal group, radiation matched group and three dose medication regimen group mouse peripheral blood leukocyte counts significantly reduce (P<0.05), and the peripheral white blood cell of irradiation control group is significantly lower than middle dosage and high dose medicament treatment group (P<0.05).
Table 5. tested material on gamma-rays irradiate mouse peripheral blood leukocyte count impact (
± s, 10
9/ L)
Note: * p<0.05 compares with Normal group, and #p<0.05 compares with radiation matched group
(2) test medicine irradiates the impact of mouse bone marrow cells DNA content in table 6 to gamma-rays.Shown in table, * represents compared with Normal group, and P<0.05 has significant difference; # represents that, compared with radiation matched group, P<0.05, has significant difference.Accept gamma-rays and irradiate latter 3rd, 7 day, compared with Normal group, radiation matched group and three dose medication regimen group mouse bone marrow cells DNA contents significantly reduce (P<0.05), and the bone marrow DNA content of irradiation control group is significantly lower than three dose medication regimen groups (P<0.05).
Table 6. tested material irradiates the impact (x ± s, μ g/ml) of mouse bone marrow cells DNA content to gamma-rays
* p<0.05 compares with Normal group, and #p<0.05 compares with radiation matched group
Accompanying drawing explanation
Fig. 1 is the influence curve figure of test medicine to CTL cell killing activity;
Fig. 2 is the influence curve figure of test medicine to NK cell killing activity;
Fig. 3 is the tumor-inhibiting action curve chart of tested material to tumor-bearing mice;
Fig. 4 is the influence curve figure of test medicine to CTL killing activity;
Fig. 5 is the influence curve figure of test medicine to NK killing activity;
Fig. 6 is the influence curve figure of test medicine to TNF-alpha levels in tumor-bearing mice serum;
Fig. 7 is the influence curve figure of test medicine to IL-2 level in tumor-bearing mice serum;
Fig. 8 is the influence curve figure of test medicine to IL-4 level in tumor-bearing mice serum;
Fig. 9 is the influence curve figure of test medicine to IFN-γ level in tumor-bearing mice serum.
Detailed description of the invention
By the following examples the present invention is described in further detail.
Embodiment 1
The preparation of radioprotective of the present invention and assistant anti-tumor drug.
1. the extraction of ginseng polysaccharide: pulverized by Radix Ginseng, adopts soxhlet extraction method to remove lipid material, the powder obtained after volatilizing, carry out water extraction, the volume adding water is 20 times of powder volume, and 95-100 DEG C of heating, extracts 2h/ time, water extraction 3 times, concentrated filtrate, adds dehydrated alcohol and carries out precipitate with ethanol, precipitate with ethanol 3 times, what obtain is precipitated as Radix Ginseng crude polysaccharides, then applies Sevag method except Deproteinization and obtain ginseng polysaccharide.
2. the extraction of lentinan: pulverized by Lentinus Edodes, adopts soxhlet extraction method to remove lipid material, the powder obtained after volatilizing, carry out water extraction, the volume adding water is 50 times of powder volume, 95-100 DEG C of heating, extract 2h/ time, water extraction 3 times, collects filtrate, concentrated filtrate, add dehydrated alcohol and carry out precipitate with ethanol, precipitate with ethanol 3 times, what obtain is precipitated as Lentinus Edodes crude polysaccharides, then applies Sevag method except Deproteinization and obtain lentinan.
3. the extraction of blazei polysaccharide: pulverized by Tricholoma matsutake (lto et lmai) Singer, adopts soxhlet extraction method to remove lipid material, the powder obtained after volatilizing, carry out water extraction, the volume adding water is 30 times of powder volume, 95-100 DEG C of heating, extract 3h/ time, water extraction 3 times, collects filtrate, concentrated filtrate, add dehydrated alcohol and carry out precipitate with ethanol, precipitate with ethanol 3 times, what obtain is precipitated as Tricholoma matsutake (lto et lmai) Singer crude polysaccharides, then applies Sevag method except Deproteinization and obtain blazei polysaccharide.
4., by the 1:1:1 mix homogeneously by weight of the powder after the ginseng polysaccharide of said extracted, lentinan and blazei polysaccharide concentrate drying, be namely prepared into the active component of radioprotective of the present invention and assistant anti-tumor drug.
This active ingredient compositions can be aided with peroral dosage form radioprotective and assistant anti-tumor drug that any pharmaceutically acceptable carrier or adjuvant can be made into any one routine.
Embodiment 2
The preparation of radioprotective and assistant anti-tumor drug capsule
Take mixture of active principles prepared by 80g embodiment 1 method and be placed in blender, slowly add 15g starch while stirring, spray into appropriate pure water, high-speed stirred 5 minutes, wet grain crosses 16 mesh sieves, puts granulate after baking oven 60 DEG C of dryings, add magnesium stearate 5g mixing, sterilizing, fills No. 0 capsule (0.25g/ capsule), obtains capsule formulation radioprotective and assistant anti-tumor drug.
Embodiment 3
The preparation of radioprotective and assistant anti-tumor drug oral liquid.
Take mixture of active principles prepared by 80g embodiment 1 method and be placed in blender, slowly add Mel 10g, sucrose 6g, citric acid 2g, magnesium stearate 2g while stirring, after mix homogeneously, add the mixing of 1L distilled water and be prepared into solution, sterilizing, be distributed into 100 bottles (10ml/ bottles), obtain oral liquid formulation radioprotective of the present invention and assistant anti-tumor drug.
Embodiment 4
The preparation of radioprotective and assistant anti-tumor drug buccal tablet.
Take mixture of active principles prepared by 80g embodiment 1 method and be placed in blender, slowly add Mel 6g, sucrose 10g, citric acid 2g, magnesium stearate 2g while stirring, add appropriate distilled water mixing drying, film-making (0.25g/ sheet) after mix homogeneously, obtain the present invention containing tablet form radioprotective and assistant anti-tumor drug.
Claims (3)
1. radioprotective and an assistant anti-tumor drug, is characterized in that, mixes obtained by extracting by decoction and alcohol sedimentation technique the ginseng polysaccharide, lentinan and the blazei polysaccharide that obtain from natural plants Radix Ginseng, Lentinus Edodes and Tricholoma matsutake (lto et lmai) Singer as active component with 1:1:1 mass ratio.
2. radioprotective according to claim 1 and assistant anti-tumor drug, is characterized in that being aided with the peroral dosage form that any one routine made by any pharmaceutically acceptable carrier or adjuvant.
3. radioprotective according to claim 1 and assistant anti-tumor drug have the application in energy adjunct antineoplastic, radioprotective and conditioner body immunity function medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310600627.6A CN103599125B (en) | 2013-11-22 | 2013-11-22 | Radioprotective and assistant anti-tumor drug and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310600627.6A CN103599125B (en) | 2013-11-22 | 2013-11-22 | Radioprotective and assistant anti-tumor drug and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103599125A CN103599125A (en) | 2014-02-26 |
| CN103599125B true CN103599125B (en) | 2016-01-20 |
Family
ID=50117433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310600627.6A Expired - Fee Related CN103599125B (en) | 2013-11-22 | 2013-11-22 | Radioprotective and assistant anti-tumor drug and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103599125B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105853994A (en) * | 2016-05-03 | 2016-08-17 | 杨洪青 | Oral liquid for resisting CT radiation and preparation method thereof |
| CN106635986B (en) * | 2016-12-02 | 2020-08-18 | 中国计量大学 | Ginseng polysaccharide for promoting proliferation and differentiation of CIK cells, culture medium, culture method and application |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100360137C (en) * | 2005-12-15 | 2008-01-09 | 吉林大学 | Antiradiation injury medicine |
| CN101643515A (en) * | 2008-08-07 | 2010-02-10 | 华中科技大学 | Method for separating and purifying lentinan for injection |
| CN103110576A (en) * | 2013-03-11 | 2013-05-22 | 河北凯盛医药科技有限公司 | Lentinan injection preparation and preparation method thereof |
-
2013
- 2013-11-22 CN CN201310600627.6A patent/CN103599125B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103599125A (en) | 2014-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Antitumor activity of polysaccharides: an overview | |
| Kodama et al. | Effects of D-Fraction, a polysaccharide from Grifola frondosa on tumor growth involve activation of NK cells | |
| Guo et al. | Immunoactive, medicinal properties of mushroom and herb polysaccharides and their potential use in chicken diets | |
| Guggenheim et al. | Immune modulation from five major mushrooms: application to integrative oncology | |
| KR100605292B1 (en) | Active fraction having anti-cancer and anti-metastasis isolated from acanthopanax species and fruits | |
| Feng et al. | Characterization and immunoenhancement activities of Eucommia ulmoides polysaccharides | |
| CN101152007B (en) | Health-care products composition and method for preparing the same | |
| CN103800661B (en) | A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation | |
| CN101020719B (en) | Composite angelica polysaccharide and its preparation process and use | |
| CN101805763B (en) | Inonotus obliquus extracellular and intracellular mixing crude polysaccharide with function of strengthening immunity | |
| CN104922181A (en) | Preparation composition containing broccoli extract with effects of improving immunity and suppressing tumors and preparation method of preparation composition | |
| JP3621404B1 (en) | Immunity enhancing active agent | |
| Liu et al. | Immunomodulatory activities of polysaccharides from white button mushroom, Agaricus bisporus (Agaricomycetes), fruiting bodies and cultured mycelia in healthy and immunosuppressed mice | |
| CN101380346B (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| CN101716256B (en) | Preparation used for strengthening immunity | |
| CN112057546A (en) | Propolis ganoderma lucidum spore powder composition and preparation method and application thereof | |
| CN103599125B (en) | Radioprotective and assistant anti-tumor drug and application | |
| CN104351612A (en) | Sea cucumber, lucid ganoderma, glucan and selenium preparation and preparation method thereof | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| Ali et al. | Therapeutic value of medicinal mushroom Agaricus blazei Murill | |
| Yin et al. | The immune effects of edible fungus polysaccharides compounds in mice. | |
| CN105999096A (en) | Composition for enhancing immunity and application | |
| CN102078600B (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| KR100548060B1 (en) | The manufacturing method of enhanced mycelium for function using herbs resourcesPuerariae Radix, Artemisiae Vulgaris Folium and its product | |
| CN101422534B (en) | Radio therapy sensitization composite preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160120 Termination date: 20171122 |